Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes ...

Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 ? February 1 in Paris, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Three-month interim data showed hyaluronic acid ...

Advocacy group alleges EU user data unlawfully sent to China Noyb's first complaint against Chinese firms China says it does not breach local laws, protects data STOCKHOLM/BRUSSELS, Jan 17 ...

In the filler pace, it has hinted at superiority over rival Galderma's Restylane-L, for example. Fourthly, and finally, Evolus' market cap valuation of $850m (back in March last year) felt low ...

"We initiated this trial because we have the unique expertise, capability, and products needed to rapidly respond to the evolving needs of patients and healthcare professionals. It is encouraging to ...

(BUSINESS WIRE )--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® LyftTM or ContourTM in combination with Sculptra® in patients ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments and boosting sales, according to dermatology group Galderma.

Nemolizumab is under clinical development by Galderma and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase III drugs for Chronic Kidney Disease ...